Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2013, Article ID 401274, 8 pages
http://dx.doi.org/10.1155/2013/401274
Research Article

Does Pro12Ala Polymorphism Enhance the Physiological Role of PPAR 2?

1Unit of Molecular Mechanisms of Disease (CISA) and Chemical and Biomolecular Sciences, School of Allied Health Sciences, Polytechnic Institute of Porto (ESTSP-IPP), Portugal
2Center of Pharmacology and Chemical Biopathology (U38-FCT), Medical Faculty, University of Porto, Portugal
3Center for Research in Health Technologies and Information Systems (CINTESIS), Medical Faculty, University of Porto, Portugal
4Biomathematics, Biostatistics and Bioinformatics, ESTSP-IPP, Porto, Portugal

Received 5 April 2013; Accepted 29 June 2013

Academic Editor: Jörg Mey

Copyright © 2013 A. C. Pereira et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. Y. Oh, K. M. Min, J. H. Chung et al., “Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-γ2 in Korean diabetic and obese subjects,” Journal of Clinical Endocrinology and Metabolism, vol. 85, no. 5, pp. 1801–1804, 2000. View at Publisher · View at Google Scholar · View at Scopus
  2. D. J. Mangelsdorf, C. Thummel, M. Beato et al., “The nuclear receptor super-family: the second decade,” Cell, vol. 83, no. 6, pp. 835–839, 1995. View at Google Scholar · View at Scopus
  3. W. He, “PPARγ2Pro12Ala polymorphism and human health,” PPAR Research, vol. 2009, Article ID 849538, 15 pages, 2009. View at Publisher · View at Google Scholar
  4. J. P. Vanden Heuvel, “The PPAR resource page,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1108–1112, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. M. Barbieri, M. R. Rizzo, M. Papa et al., “Role of interaction between variants in the PPARG and interleukin-6 genes on obesity related metabolic risk factors,” Experimental Gerontology, vol. 40, no. 7, pp. 599–604, 2005. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Kersten and W. Wahli, “Peroxisome proliferator activated receptor agonists,” EXS, vol. 89, pp. 141–151, 2000. View at Google Scholar · View at Scopus
  7. A. Ciccodicola, V. Costa, A. Casamassimi et al., “Characterization of a novel polymorphism in PPARG regulatory region associated with type 2 diabetes and diabetic retinopathy in italy,” Journal of Biomedicine and Biotechnology, vol. 2009, Article ID 126917, 7 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  8. R. Valve, K. Sivenius, R. Miettinen et al., “Two polymorphisms in the peroxisome proliferator-activated receptor-γ gene are associated with severe overweight among obese women,” Journal of Clinical Endocrinology and Metabolism, vol. 84, no. 10, pp. 3708–3712, 1999. View at Google Scholar · View at Scopus
  9. K. Clement, S. Hercberg, B. Passinge et al., “The Pro115Gln and Pro12Ala PPAR gamma gene mutations in obesity and type 2 diabetes,” International Journal of Obesity, vol. 24, no. 3, pp. 391–393, 2000. View at Google Scholar · View at Scopus
  10. J. Schneider, J. Kreuzer, A. Hamann, P. P. Nawroth, and K. A. Dugi, “The proline 12 alanine substitution in the peroxisome proliferator-activated receptor-γ2 gene is associated with lower lipoprotein lipase activity in vivo,” Diabetes, vol. 51, no. 3, pp. 867–870, 2002. View at Google Scholar · View at Scopus
  11. J. Delarue and C. Magnan, “Free fatty acids and insulin resistance,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 10, no. 2, pp. 142–148, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. G. D. Tan, M. J. Neville, E. Liverani et al., “The in vivo effects of the Pro12Ala PPARγ2 polymorphism on adipose tissue NEFA metabolism: the first use of the Oxford Biobank,” Diabetologia, vol. 49, no. 1, pp. 158–168, 2006. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Stumvoll, “Reduced lipolysis as possible cause for greater weight gain in subjects with the Pro12Ala polymorphism in PPARγ2?” Diabetologia, vol. 45, no. 1, pp. 152–153, 2002. View at Publisher · View at Google Scholar · View at Scopus
  14. M. Stumvoll, H. G. Wahl, K. Löblein, R. Becker, F. Machicao, and H. Häring, “Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with increased antilipolytic insulin sensitivity,” Diabetes, vol. 50, no. 4, pp. 876–881, 2001. View at Google Scholar · View at Scopus
  15. X. Formiguera and A. Cantón, “Obesity: epidemiology and clinical aspects,” Best Practice and Research, vol. 18, no. 6, pp. 1125–1146, 2004. View at Publisher · View at Google Scholar · View at Scopus
  16. P. Zimmet and K. G. M. M. Alberti, “Global and societal implications of the diabetes epidemic,” Nature, vol. 414, no. 6865, pp. 782–787, 2001. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Ghoussaini, D. Meyre, S. Lobbens et al., “Implication of the Pro12Ala polymorphism of the PPAR-gamma 2 gene in type 2 diabetes and obesity in the French population,” BMC Medical Genetics, vol. 6, article11, 2005. View at Publisher · View at Google Scholar · View at Scopus
  18. J. L. González Sánchez, M. Serrano Ríos, C. Fernández Pérez, M. Laakso, and M. T. Martínez Larrad, “Effect of the Pro12Ala polymorphism of the peroxisome proliferator-activated receptor γ-2 gene on adiposity, insulin sensitivity and lipid profile in the Spanish population,” European Journal of Endocrinology, vol. 147, no. 4, pp. 495–501, 2002. View at Google Scholar · View at Scopus
  19. S. Ereqat, A. Nasereddin, K. Azmi, Z. Abdeen, and R. Amin, “Impact of the pro12Ala polymorphism of the PPAR-gamma 2 gene on metabolic and clinical characteristics in the palestinian type 2 diabetic patients,” PPAR Research, vol. 2009, Article ID 874126, 5 pages, 2009. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Ben Ali, F. Ben Yahia, Y. Sediri et al., “Gender-specific effect of Pro12Ala polymorphism in peroxisome proliferator-activated receptor γ-2 gene on obesity risk and leptin levels in a Tunisian population,” Clinical Biochemistry, vol. 42, no. 16-17, pp. 1642–1647, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. V. I. Lindi, M. I. J. Uusitupa, J. Lindström et al., “Association of the Pro12Ala polymorphism in the PPAR-γ2 gene with 3-year incidence of type 2 diabetes and body weight change in the Finnish Diabetes Prevention Study,” Diabetes, vol. 51, no. 8, pp. 2581–2586, 2002. View at Google Scholar · View at Scopus
  22. D. A. Chistiakov, V. A. Potapov, D. S. Khodirev, M. S. Shamkhalova, M. V. Shestakova, and V. V. Nosikov, “The PPARγ Pro12Ala variant is associated with insulin sensitivity in Russian normoglycaemic and type 2 diabetic subjects,” Diabetes and Vascular Disease Research, vol. 7, no. 1, pp. 56–62, 2010. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Z. Bouassida, L. Chouchane, K. Jellouli et al., “The peroxisome proliterator activated receptorγ2 (PPARγ2) Pro12Ala variant: lack of association with type 2 diabetes in obese and non obese Tunisian patients,” Diabetes and Metabolism, vol. 31, no. 2, pp. 119–123, 2005. View at Google Scholar · View at Scopus
  24. M. T. Malecki, J. Frey, T. Klupa et al., “The Pro12Ala polymorphism of PPARγ2 gene and susceptibility to type 2 diabetes mellitus in a Polish population,” Diabetes Research and Clinical Practice, vol. 62, no. 2, pp. 105–111, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. D. Pintérová, M. Cerná, K. Kolostová et al., “The frequency of alleles of the Pro12Ala polymorphism in PPARgamma2 is different between healthy controls and patients with type 2 diabetes,” Folia Biologica, vol. 50, no. 5, pp. 153–156, 2004. View at Google Scholar
  26. H. Mori, H. Ikegami, Y. Kawaguchi et al., “The Pro12→Ala substitution in PPAR-γ is associated with resistance to development of diabetes in the general population: possible involvement in impairment of insulin secretion in individuals with type 2 diabetes,” Diabetes, vol. 50, no. 4, pp. 891–894, 2001. View at Google Scholar · View at Scopus